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Abstract 
Primary carcinomas of the female urethra
are extremely rare, with an annual incidence
of less than ten in one million. Currently, there
is no consensus regarding management of this
malignancy. However, there have been several
case  reports  demonstrating  the  efficacy  of
chemoradiation  in  the  treatment  of  female
urethral cancer. In this report we present two
cases  of  female  primary  urethral  adenocar  -
cinoma  that  were  treated  by  concomitant
chemotherapy  and  external  beam  radiother  -
apy, followed by interstitial brachytherapy.  
Introduction
Primary carcinomas of the female urethra
are extremely rare, and because most present
at an advanced stage the overall prognosis is
poor.
1 Owing to the rarity of this disease, there
is  no  consensus  on  the  management  of  pr  -
imary female urethral cancer.
2-7 Managed with
surgery alone, five-year disease-free survival
is only 20-30%. Radiotherapy and chemother  -
apy have been advocated in combination with
surgery to improve treatment outcomes.
2-15
Several studies have shown that interstitial
brachytherapy  is  an  effective  modality,  used
alone  or  in  combination  with  other  treat-
ments.
5,15-17 In a study of 34 women with pri-
mary  urethral  cancer,  Milosevic  et  al. found
that adding interstitial brachytherapy to exter-
nal beam radiation reduced the risk of local
recurrence by a factor of 4.2.
5 Foens et al. treat-
ed 28 cases of female primary urethral cancer
and found that the three-year disease-free sur-
vival  rates  were  29%  for  those  treated  with
external  beam  radiation  alone,  and  57%  for
those  treated  with  combined  external  and
interstitial  radiotherapy.
16 The  addition  of
chemosensitization, for example, cisplatin, to
the radiation therapy regimen is also thought
to increase local control and survival.
2,18
In this case report, we describe two cases of
female primary urethral adenocarcinoma that
have been managed successfully with external
beam radiation and concomitant chemother  -
apy  (cisplatin  and  capecitabine)  followed  by
interstitial brachytherapy.
Materials and Methods
Case #1
A 53-year-old white female presented with
progressive dysuria, hematuria, and ultimately
urinary  retention.  On  physical  examination
she had a 4-cm peri-urethral mass. Cystoscopy
revealed a urethral tumor involving the entire
length of the urethra with extension into, but
not invading, the bladder. The biopsy was con-
sistent with a well-to-moderately differentiated
adenocarcinoma.  T2-weighted  magnetic
reson  ance  imaging  (MRI)  demonstrated  a
mildly hyperintense 7.2ﾥ3.0ﾥ2.8-cm fungating
mass in the proximal urethra with invasion of
the  anterior  wall  of  the  distal  vagina.  The
tumor  was  staged  as  stage  II  (cT2N0M0).
Trans  urethral resection of a small intravesical
portion  of  the  tumor  was  performed.  The
patient then received external beam radiation
therapy with concomitant cisplatin (40 mg/m
2
weekly) and capecitabine (500 mg twice daily,
5 days/week). The whole pelvis received 30 Gy
delivered in 15 fractions, followed by an add  -
itional 20 Gy delivered in 10 fractions to the
lower  pelvis.  Therapy  was  given  with  AP/PA
fields using 6 and 15 MV photons on a Varian
2300  linear  accelerator.  Custom  blocks  were
used to spare normal tissues. The patient toler-
ated the therapy well, with only mild diarrhea
and perineal dermatitis as side-effects.  
Approximately  two  weeks  after  external
beam radiation therapy was completed, inter-
stitial low-dose rate (LDR) brachytherapy was
performed  using  transrectal  ultrasound  and
fluoroscopic  guidance.  Five  interstitial
catheters  were  loaded  approximately  1-cm
apart with 32 
192Ir sources. A 2-cm diameter
vaginal  cylinder  was  placed  in  the  vaginal
vault, which was loaded with three 5-mg ra  -
dium equivalent 
137Cs sources. The brachyther-
apy dose was 25 Gy prescribed in addition to
the 60 cGy per hour isodose line. Treatment
planning was performed on the ROCS planning
system,  using  orthogonal  X-ray  films.  The
patient tolerated therapy well, with only dys-
pareunia  as  a  side-effect.  At  completion  of
therapy she had normal urinary voiding func-
tion and urinary continence.
Sixteen months later, the patient presented
with headache, dizziness, and diplopia. MRI of
the brain revealed a heterogeneously enhan  -
cing 2.0ﾥ2.7ﾥ2.7-cm mass in the cerebellum.
The  biopsy  was  consistent  with  metastatic 
adenocarcinoma,  and  appeared  histologically
similar to her urethral tumor. The cerebellar
tumor  was  neurosurgically  resected.
Postoperative external beam radiation therapy
was delivered to the posterior fossa to a pre-
scribed dose of 30 Gy in 10 fractions using 6
MV photons with opposed lateral fields. The
patient tolerated therapy well. A follow-up MRI
of the brain 15 months after the surgery and
radiotherapy showed no recurrence of disease.
A follow-up pelvic examination showed no evi-
dence of recurrent disease three years follow-
ing chemoradiation.
Case #2
A 67-year-old white female presented with
recurrent urinary tract infections (UTIs) and
urinary retention. On examination, she had a
4-cm peri-urethral mass; the biopsy showed a
poorly differentiated adenocarcinoma. MRI of
the pelvis revealed an enhancing 4.1ﾥ3.5ﾥ4.1-
cm peri-urethral mass with possible involve-
ment of the inferior bladder. The tumor was
staged as a stage II (cT2N0M0) adenocarcin  -
oma of the urethra. The patient received exter-
nal beam radiation therapy with concomitant
cisplatin (40 mg/m
2 weekly) and capecitabine
(500 mg twice daily, 5 days/week). A prescribed
dose of 46 Gy was delivered in 23 fractions to
the tumor, as well as to inguinal and pelvic
lymph nodes. Therapy was given with AP/PA
fields using 6 and 15 MV photons on a Varian
2300  linear  accelerator.  Custom  blocks  were
used  to  spare  normal  tissues.  The  patient
tolera  ted external beam therapy well, with only
diarrhea,  urge  incontinence,  and  superficial
ulcerative moist desquamation of the inguinal
folds as side-effects. At completion of therapy
she had normal urinary voiding function and
urinary continence.
Approximately  four  weeks  after  external
beam  radiation  was  completed,  interstitial
high-dose rate (HDR) brachytherapy was per-
formed using transvaginal ultrasound with a
perineal template for needle guidance (Figure
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1). Seven interstitial brachytherapy flexi-nee-
dles  were  placed  in  the  tumor.  A  treatment
planning CT of the pelvis was then performed,
and  the  CT  images  were  transferred  to  the
treatment planning system (Brachyvision 7.1,
Varian Inc, Sunnyvale CA). The tumor and ur  -
ethra  were  contoured,  and  the  indwelling
times in each catheter were adjusted manually
to deliver an optimized dose of 5 Gy/fraction to
the tumor, for a total of 20 Gy (Figures 2 and
3), given over three days.   
After interstitial HDR treatments had been
completed,  the  template  was  removed  (with
the needles kept in place) so that an MRI could
be  performed.  The  MR  images  were  trans-
ferred to the treatment planning system and
fused with the treatment planning CT images,
using the needle locations as the registration
points. The tumor was more easily visualized
on the MRI data set than on the CT data set.
The tumor and urethra were contoured on the
MR image set for comparison with those struc-
tures on the CT image set (Figure 4).  
The  fused  images  showed  that  the  tumor
was adequately treated. A follow-up MRI, per-
formed three months after the brachytherapy
treatment,  showed  no  residual  tumor  mass.
Fourteen months after treatment, the patient
has no evidence of disease recurrence, radio  -
graphically or on a physical examination.
Results and Discussion
Primary urethral cancer is rare, comprising
less  than  1%  of  all  malignancies.
4 A  recent
review  of  the  National  Cancer  Institute
Surveillance,  Epidemiology,  and  End  Results
database  showed  that  1,075  men  and  540
women were diagnosed with primary urethral
cancer in the United States from 1973 to 2002,
the major histological types being transitional
cell carcinoma (55%), squamous cell carcin  -
oma (21.5%), and adenocarcinoma (16.4%).
1
The histology of the neoplasm, however, does
not seem to affect prognosis.
2,4,5
Multiple factors have been correlated with
the outcome in women with urethral cancer.
This is well illustrated in a series of 72 women
treated  at  Memorial  Sloan-Kettering  over  a
period of 36 years.
12 In this study, multivariate
analysis showed that the stage of the primary
tumor,  the  presence  or  absence  of  regional
lymph node involvement, and the site of dis-
ease (proximal versus distal urethra) were all
independent  risk  factors  for  survival.  For
example, patients with tumors ≤2 cm in size in
the distal urethra had a 60% five-year survival
rate, while those with lesions >4 cm in size in
the proximal urethra had a five-year survival
rate of only 13%. Others have also demonstrat-
ed  that  small,  distal  tumors  have  relatively
good  prognoses,  whereas  larger,  proximal
tumors  carry  relatively  poor  prognoses.
2-14
Overall prognosis, however, remains relatively
poor, with a five-year overall survival rate of
approximately 35-45%.
2-5
Multiple small case studies have suggested
that  single  modality  treatment  (surgery  or
radiation therapy) is effective for small, distal
tumors; on the other hand, multimodal treat-
ment has been recommended for larger and
more proximal tumors.
3-5,7,8,15 Other case reports
have suggested that brachytherapy is an effect  -
ive component of multimodality treatment of
primary urethral cancer.
5,8,16,17 Our case report
corroborates  the  assertion  that  larger,  prox  -
imal  tumors  may  be  effectively  treated  with
chemoradiotherapy,  and  that  interstitial
brachytherapy appears to be a significant com-
ponent of this treatment approach.  
The use of advanced imaging technologies,
including transvaginal ultrasound to guide the
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Figure 1. Transverse ultrasound image of
the tumor for case #2.
Figure 3. Computer tomography images of
the tumor with the 5 Gy isodose line (blue)
for case #2.
Figure 4. Contours from the fused com  -
puter tomography and magnetic resonance
images for Case #2. The magnetic reson  -
ance tumor volume is in green, the com-
puted tomography tumor volume is in red,
the magnetic resonance urethra is in blue,
the  computed  tomography  urethra  is  in
yellow.
Figure 2. Computer tomography images of the tumor (red contour) and urethra (yellow
contour) along with the interstitial needles for case # 2.[page 160] [Rare Tumors 2010; 2:e55]
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placement  of  interstitial  needles  along  with
MRI and CT scans, allows for improved diagno-
sis  and  treatment  of  urethral  cancer.
19-25
Further  advancement  of  the  treatment  plan-
ning can be made by the utilization of ultra-
sound-based  planning  (Vitesse,  Varian).
Vitesse allows the capture of ultrasound data
and its conversion to DICOM RT, which can
then  be  exported  to  the  BrachyVision  treat-
ment planning system. The use of ultrasound
in planning would shorten the work flow by
eliminating the need for a CT scan, and would
also  provide  excellent  imaging  of  the  tumor
along with the implanted needles.
Conclusions
There are no consensus recommendations
for the treatment of primary female urethral
cancer owing to the rarity of this disease and
the paucity of information in the literature. As
such, the reporting of all cases of primary ur  -
ethral cancer is necessary to better determine
optimal management. Many authors have sug-
gested a combination of surgery, chemosensi-
tization,  and  radiation  therapy.  This  case
report supports the assertion that interstitial
brachytherapy  after  chemoradiation  is  an
effective  and  well-tolerated  treatment  option
for female primary urethral adenocarcinoma.
In  the  two  patients  presented  in  this  case
study,  the  responses  to  therapy  have  been
excellent with only relatively mild side-effects. 
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